secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001689375-22-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics reports Q3 2022 net loss of $25.1M; cash runway into H2 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $215.6M as of Sept 30, 2022, down from $291.1M at Dec 31, 2021.
- Net loss for Q3 2022 was $25.1M, compared to $14.4M in Q3 2021.
- R&D expenses increased to $19.0M (Q3 2022) from $10.5M (Q3 2021); G&A expenses rose to $7.0M from $3.9M.
- On track to file IND for ENTR-601-44 (Duchenne exon 44 skipping) in Q4 2022; second IND for ENTR-701 (DM1) planned for H2 2023.
- Preclinical data for ENTR-701 presented at World Muscle Society; collaboration entered with Myotonic Dystrophy Clinical Research Network.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/0001689375-22-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937522000043/trda-20221107.htm
  HTML page:      https://secwatch.observer/filing/0001689375-22-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer